How should anti-amyloid trial results be interpreted when amyloid PET changes substantially but CDR-SB or iADRS changes remain near clinical meaningfulness thresholds?

Evidence span

How should anti-amyloid trial results be interpreted when amyloid PET changes substantially but CDR-SB or iADRS changes remain near clinical meaningfulness thresholds?

Method & conditions

Evidence type

theoretical

Method

manual state transition

Conditions

Candidate gap for maintainer review; not a guaranteed experiment target.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required